Janux Therapeutics Inc Net Assets
Janux Therapeutics Inc net assets. Based on the latest financial reports, Janux Therapeutics Inc (JANX) has net assets worth $941.53 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.03 Billion) and total liabilities ($86.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore JANX net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $941.53 Million |
| % of Total Assets | 91.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | 161.19% |
| 10-Year Change | N/A |
| Growth Volatility | 87.27 |
Net Assets of Janux Therapeutics Inc (2019–2025)
Net assets of Janux Therapeutics Inc from 2019 to 2025. This chart illustrates how Janux Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Janux Therapeutics Inc (JANX) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Janux Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Janux Therapeutics Inc from 2019 to 2025. For live market cap and overall valuation, see Janux Therapeutics Inc (JANX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $956.82 Million | -6.45% |
| 2024-12-31 | $1.02 Billion | +197.02% |
| 2023-12-31 | $344.35 Million | +7.36% |
| 2022-12-31 | $320.74 Million | -12.44% |
| 2021-12-31 | $366.33 Million | +2602.58% |
| 2020-12-31 | $-14.64 Million | -84.26% |
| 2019-12-31 | $-7.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Janux Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34342700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Janux Therapeutics Inc Net Assets Breakdown (December 2025)
Janux Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.00K | 0.01% |
| Other Comprehensive Income | $4.32 Million | 0.45% |
| Other Components | $1.30 Billion | 136.27% |
| Total Equity | $956.82 Million | 100.00% |
Janux Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Janux Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JM AB (publ)
ST:JM
|
$878.83 Million |
|
Jaya Real Property Tbk
JK:JRPT
|
$879.10 Million |
|
Cisen Pharmaceutical Co Ltd
SHG:603367
|
$879.17 Million |
|
Run Long Construction Co Ltd
TW:1808
|
$879.23 Million |
|
Henan Jindan Lactic Acid Technology
SHE:300829
|
$878.00 Million |
|
Mirle Automation Corp
TW:2464
|
$877.66 Million |
|
Guangzhou Fangbang Electronics Co Ltd
SHG:688020
|
$877.63 Million |
|
Guangzhou Newlife New Material Co. Ltd. A
SHE:301323
|
$877.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Janux Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,022,781,000 to 956,822,000, a change of -65,959,000 (-6.4%).
- Net loss of 113,625,000 reduced equity.
- Share repurchases of 347,000 reduced equity.
- Other comprehensive income increased equity by 2,153,000.
- Other factors increased equity by 45,860,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-113.62 Million | -11.88% |
| Share Repurchases | $347.00K | -0.04% |
| Other Comprehensive Income | $2.15 Million | +0.23% |
| Other Changes | $45.86 Million | +4.79% |
| Total Change | $- | -6.45% |
Book Value vs Market Value Analysis
This analysis compares Janux Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.19 | $17.63 | x |
| 2020-12-31 | $-0.35 | $17.63 | x |
| 2021-12-31 | $8.88 | $17.63 | x |
| 2022-12-31 | $7.73 | $17.63 | x |
| 2023-12-31 | $7.82 | $17.63 | x |
| 2024-12-31 | $19.03 | $17.63 | x |
| 2025-12-31 | $15.44 | $17.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Janux Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1136.25%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.05x
- Recent ROE (-11.88%) is below the historical average (-8.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.44 Million |
| 2020 | 0.00% | -1785.26% | 0.02x | 0.00x | $-5.32 Million |
| 2021 | -8.89% | -895.22% | 0.01x | 1.04x | $-69.19 Million |
| 2022 | -16.88% | -628.82% | 0.02x | 1.13x | $-86.23 Million |
| 2023 | -16.93% | -721.18% | 0.02x | 1.10x | $-92.73 Million |
| 2024 | -6.75% | -651.62% | 0.01x | 1.04x | $-171.27 Million |
| 2025 | -11.88% | -1136.25% | 0.01x | 1.05x | $-209.31 Million |
Industry Comparison
This section compares Janux Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $194,529,907
- Average return on equity (ROE) among peers: -57.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Janux Therapeutics Inc (JANX) | $941.53 Million | 0.00% | 0.09x | $878.78 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $25.47 Million |
| Abcellera Biologics Inc (ABCL) | $966.90 Million | -15.14% | 0.40x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $238.46 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $16.14 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $10.73 Million | -115.68% | 0.96x | $724.08 Million |
| ABVC Biopharma Inc (ABVC) | $-1.24 Million | 0.00% | 0.00x | $25.82 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.48 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $627.01 Million | -44.91% | 0.25x | $3.66 Billion |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more